Larimar Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LRMR research report →
Range $5 – $9
Price Chart
About the company
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform.
- CEO
- Carole S. Ben-Maimon
- IPO
- 2014
- Employees
- 71
- HQ
- Bala Cynwyd, PA, US
Get TickerSpark's AI analysis on LRMR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $328.55M
- P/E
- -2.17
- Fwd P/E
- 12.31
- PEG
- -0.09
- P/S
- 0.00
- P/B
- 3.06
- EV/EBITDA
- -1.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -134.23%
- ROIC
- -152.44%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-172,497,000
- Net Income
- $-165,673,000-105.5%
- EPS
- $-2.27-72.0%
- OCF Growth
- -60.0%
- FCF Growth
- -59.0%
- 52W High
- $6.42
- 52W Low
- $1.92
- 50D MA
- $2.87
- 200D MA
- $3.76
- Beta
- 0.69
- RSI (14)
- 63
- Avg Volume
- 1.36M
No earnings-call transcripts are available for LRMR yet.
- Free Float
- 55.3%
- Shares Outstanding
- 103.88M
- Float Shares
- 57.43M
of shares held by institutions
171 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Deerfield Management Company, L.P. | 35.61M | 0 |
| Blue Owl Capital Holdings LP | 9.92M | ▲ 760.75K |
| Rtw Investments, LP | 5.82M | ▲ 3.25M |
| Blackrock, Inc. | 5.77M | ▲ 92.14K |
| Defilade Capital Management, L.P. | 4.93M | ▲ 1.26M |
| Driehaus Capital Management LLC | 3.13M | ▼ 34.75K |
| Vanguard Group Inc | 3.05M | ▼ 41.62K |
| Vanguard Capital Management LLC | 2.97M | 0 |
| Goldman Sachs Group Inc | 2.97M | ▲ 1.22M |
| Aqr Capital Management LLC | 2.24M | ▼ 130.79K |
| Marshall Wace, Llp | 2.20M | ▲ 183.50K |
| Dafna Capital Management LLC | 1.89M | ▼ 120.01K |
Held by 137 ETFs
Biggest fund positions in LRMR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Clayton Russell | buy | 3,322 |
| Nov 16, 26 | SHERMAN JEFFREY W | buy | 3,289.474 |
| Nov 12, 26 | Hamilton Thomas Edward | buy | 70,000 |
| Nov 11, 26 | BEN-MAIMON CAROLE | buy | 18,050 |
| Nov 11, 26 | THOMAS FRANK E | buy | 8,000 |
| Nov 11, 26 | Truitt Joseph | buy | 3,500 |
| Nov 11, 26 | Harlow John B. Jr. | buy | 17,800 |
| Nov 11, 26 | Celano Michael | buy | 18,460 |
| Nov 11, 26 | Shankar Gopi | buy | 5,000 |
| Sep 29, 26 | Harlow John B. Jr. | other | 800,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LRMR coverage
Recent articles, reports, and earnings notes.
No research on LRMR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LRMR report →Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
globenewswire.com · Nov 16
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich's Ataxia
globenewswire.com · Nov 9
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
globenewswire.com · Nov 5
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
globenewswire.com · Nov 4
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
marketbeat.com · Oct 10
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com · Oct 5
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
globenewswire.com · Sep 29
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
zacks.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.